Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 - Wikidata - wikimedia - TriplyDB

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

http://www.wikidata.org/entity/Q28179431

about

Preparing synthetic biology for the world Immunology of Crohn's Disease Innate immunity in inflammatory bowel disease: a disease hypothesis Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii Protease inhibition as new therapeutic strategy for GI diseases Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures Synthetic biology and occupational risk New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models Biocontainment of genetically modified organisms by synthetic protein design Rational design of improved pharmabiotics Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis.Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens.(Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease Insertional inactivation of determinants for Mg2+ and Co2+ transport as a tool for screening recombinant Lactococcus species clones.Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice.Biology by design: from top to bottom and back Development of Streptococcus pneumoniae Vaccines Using Live Vectors Programmable cells: interfacing natural and engineered gene networks Enhancement of Th1-biased protective immunity against avian influenza H9N2 virus via oral co-administration of attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-α and interleukin-18 along with an inactivated vaccine.Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium 3D domain swapping causes extensive multimerisation of human interleukin-10 when expressed in planta.Efficacy of a Lactococcus lactis ΔpyrG vaccine delivery platform expressing chromosomally integrated hly from Listeria monocytogenes Evolution, ecology and the engineered organism: lessons for synthetic biology.Live bacterial vaccines--a review and identification of potential hazards.Multilayered genetic safeguards limit growth of microorganisms to defined environments Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.Synthetic microbes as drug delivery systems.Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.IL-10 and its related cytokines for treatment of inflammatory bowel disease.Complete genome sequence of the prototype lactic acid bacterium Lactococcus lactis subsp. cremoris MG1363.

P2860

Q21131128-3636C78F-1B92-4782-8890-316FA488CC4D Q22241677-A95B035A-E127-416C-96F8-FD1A9FB10053 Q22252859-D9620090-D372-45F5-AA12-FF73A0A09A8F Q24799750-D40C558E-4513-4145-9310-FD40B27ACC61 Q24804214-B331CDE2-0527-4ACB-8C72-390EAA28DAAC Q26747722-E35265CE-E2DD-44D6-9956-A966D5C3F768 Q26753101-D65C0C77-94BF-41ED-BB61-3A588D3E4EF4 Q26786083-C9F57953-1BC8-4597-8F8D-D03284A2FA83 Q27028100-BE2F7673-39F8-489D-B9F7-31D3DE3AF7C8 Q27486575-2788F047-87E0-4611-B840-BB733E16B990 Q27968974-9181C44A-C463-401E-BAC6-7989FA5D4D41 Q28079638-6C8C41DE-1A02-40B4-B8CE-F886E92AD799 Q28083627-7A0C7855-E191-4FBF-804B-64489A4AD3DD Q28255773-85886C82-82CA-498E-AE1F-D73A17D760C6 Q28258559-229D3730-F6C8-453F-A02B-841C6996C0B2 Q30852941-4723BAEA-58A6-4532-B772-4637580751D9 Q33496351-EAE0B63F-1D3D-494D-8503-4B36174FD82E Q33578069-24974E8A-CB0B-4812-B018-2B1C994ACEE8 Q33650357-D98D6E66-F9E7-442F-9636-89F7163632E4 Q33651733-E94315EB-AB3D-4C2D-A815-A246A2BD9C2D Q33909216-9EEFC125-B5D9-4D92-B70B-B97B5822E8E4 Q33913171-DF4B8B92-E076-4EB4-AC3A-9E8A898A8FB5 Q34030833-A1B6F093-A46F-4DEA-B224-C5FA85160025 Q34089896-50D30AE0-3D15-49B4-837C-6B604B240E24 Q34271428-8D33B48D-B087-42D4-8144-E3BC71A1CC14 Q34316015-DD6563A7-616C-4F85-B227-C661FD9173A8 Q34322635-09171FEC-E6A8-4B1B-85FB-E86458BF890B Q34331463-9DAE9111-1FE7-47FB-8A03-62F59A552A2A Q34344893-AC4C0A87-EB4B-4A2F-9242-3908F40A68E8 Q34437671-7F43F89F-D2BD-418F-8DAD-64114DBB18DD Q34558223-AE63155D-F5BF-4462-9A8D-3BE9F7BE1091 Q34964484-9B8A3A9F-F91B-4FDA-B2DD-B33F5BFDFA64 Q34974711-50401958-CDB0-4F0F-B40B-B14A73022DF8 Q35088968-E9E7B6DB-35D7-4392-ADA1-D6E67B799308 Q35215742-2C680DF3-6879-44A9-9613-3FFB82A00949 Q35417757-EACF4488-FAF5-42EA-B0AA-5A1122AAB05F Q35541972-1BF34F3F-2ED5-4208-AF12-EF7B77454D2A Q35596025-F2417BFE-7793-403D-B771-7DB905285607 Q35678651-7CB07DF4-C7CC-4056-94EA-1897C34D501C Q35759658-605845F7-5362-4E86-BE98-18E9C99BBD7B

P2860

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

http://www.wikidata.org/entity/Q28179431

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Biological containment of gene ...... livery of human interleukin 10

@ast

Biological containment of gene ...... livery of human interleukin 10

@en

Biological containment of gene ...... livery of human interleukin 10

@nl

type

label

Biological containment of gene ...... livery of human interleukin 10

@ast

Biological containment of gene ...... livery of human interleukin 10

@en

Biological containment of gene ...... livery of human interleukin 10

@nl

prefLabel

Biological containment of gene ...... livery of human interleukin 10

@ast

Biological containment of gene ...... livery of human interleukin 10

@en

Biological containment of gene ...... livery of human interleukin 10

@nl

P1433

Q28179431-53D1BD5E-9A0D-4C36-9232-4DC2891C3734

P1476

Q28179431-BF71309C-15F6-4110-A121-FD8D65599412

P2093

Q28179431-40771FCC-C9B2-4F49-A16A-8265443641CD

Q28179431-59E742AD-8C62-4D60-B4EE-E695517570CF

Q28179431-5EAB4941-4C1B-47A7-8321-638D50BA686F

Q28179431-996A1D17-530D-45DC-94DF-373B1FA39937

Q28179431-A9F22922-D034-40D3-BAE4-60F5B1B0552E

Q28179431-B294F628-2360-4316-A148-803663EC4ECB

Q28179431-C68CAEBD-9AD3-4EFB-BC8C-B2F588464F07

P2888

Q28179431-4F8BD553-9E4E-4DD8-B8B6-7C7B46D05CF8

P304

Q28179431-A1184B5B-2696-4432-A4FF-8401D3D87EB5

P31

Q28179431-D188A259-228D-41D7-8F78-56E8F16BB46A

P3181

Q28179431-1DAC668A-862C-4F8D-BB9A-D0371B6C0535

P356

Q28179431-7A1E4BE2-04E0-4585-A63B-D7FED2DE5EDF

P407

Q28179431-6C2208A3-6444-4188-8856-0801331891F2

P433

Q28179431-776AC5DE-B25F-4429-9F71-7971330EA814

P478

Q28179431-0CFF1CE7-C71D-4C3A-B532-30DBBEF44059

P50

Q28179431-0D33F454-1E49-450C-8B80-AE8E7E91818D

Q28179431-C73270EC-0F61-4D01-8FAF-FDD3AE6C3C34

P577

Q28179431-07E6A1CC-B887-4745-8CF2-E17978249444

P5875

Q28179431-F610E3AA-96F0-4E64-A773-39B88EDF12DF

P698

Q28179431-531593BE-4344-4583-A14D-F099583261CD

P921

Q28179431-98d38cb6-7d0a-4da6-9212-806caf1aa1ed

P3181

P356

P1433

Nature Biotechnology

P1476

Biological containment of gene ...... livery of human interleukin 10

@en

P2093

An Vermeire

http://www.w3.org/2001/XMLSchema#string

Erik Remaut

http://www.w3.org/2001/XMLSchema#string

Jean Paul Remon

http://www.w3.org/2001/XMLSchema#string

Lothar Steidler

http://www.w3.org/2001/XMLSchema#string

Nathalie Huyghebaert

http://www.w3.org/2001/XMLSchema#string

Sabine Neirynck

http://www.w3.org/2001/XMLSchema#string

Veerle Snoeck

http://www.w3.org/2001/XMLSchema#string

P2888

P304

785-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1897230

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NBT840

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Bruno Goddeeris

P577

2003-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10707540

http://www.w3.org/2001/XMLSchema#string

P698

12808464

http://www.w3.org/2001/XMLSchema#string

P921